Ridglan Farms, a beagle breeding facility in Dane County, Wisconsin that supplied dogs to research laboratories for decades, has permanently shut down. About 1,500 beagles were transferred to rescue organizations as part of a negotiated deal, according to The Guardian. Big Dog Ranch Rescue, a cage-free shelter, took in hundreds of those animals. The Center for a Humane Economy, an advocacy group, helped broker the agreement.

Why beagles in research, and why this facility?

Beagles are the default choice for certain kinds of laboratory testing — toxicology and pharmacokinetics studies, which measure how drugs move through the body. Their small size, docile temperament, and predictable genetics make them practical for controlled lab protocols. Facilities like Ridglan existed to supply that demand through a regulated pipeline to contract research organizations and pharmaceutical companies.

Ridglan's closure removes one source from that supply chain at a moment when it's already under pressure. The Center for a Humane Economy has pursued similar negotiations with other facilities in recent years, typically combining legal pressure, public campaigns, and direct talks with operators. A negotiated exit — where the facility transfers its animals rather than face prolonged enforcement actions by the USDA — has become the preferred approach for advocacy groups. It's faster than regulatory enforcement and lets operators exit with a clear path forward.

The immediate and longer-term challenge

The closure does not eliminate the demand. Laboratories that rely on purpose-bred beagles will find other suppliers. The market itself does not vanish when one facility closes.

The larger question is whether alternatives to animal testing will gain regulatory acceptance fast enough to actually shrink that demand. These alternatives exist: organ-on-a-chip platforms (tiny tissue models that simulate organ function), advanced lab-grown cell assays, and computer models of toxicology. In late 2022, the FDA Modernization Act 2.0 removed the legal requirement for animal testing in drug development, giving regulators the discretion to accept alternatives. But adoption has been slow and uneven.

For Big Dog Ranch Rescue, the practical challenge is substantial. Purpose-bred research dogs have rarely been socialized to normal domestic life. They need structured behavioral rehabilitation before they can be adopted into homes. Transport, veterinary screening, and the foster-to-adoption pipeline at the scale of hundreds of animals is logistically demanding, even for an experienced no-kill organization.

The negotiated closure model, for all its limitations, now has another case study. Whether this approach becomes a template for shutting down similar facilities, or remains a one-off victory, depends partly on whether regulators and lawmakers continue to tighten the rules around animal research — and partly on whether labs find it economically worthwhile to shift to alternatives.